Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer

被引：5
|
作者：
Knoedler, M.
Gauler, T. C.
Matzdorff, A.
Dietz, A.
Gruenwald, V.
Arnold, D.
Hennemann, B.
Schroeder, M.
Hofele, C.
Schmittel, A.
Keilholz, U.
机构：
[1] Charite, D-13353 Berlin, Germany
[2] Univ Klinikum Essen, Essen, Germany
[3] Caritasklin, Saarbrucken, Germany
[4] Univ Klinikum Leipzig, Leipzig, Germany
[5] Hannover Med Sch, D-30623 Hannover, Germany
[6] Univ Klinikum Halle, Halle, Germany
[7] Univ Klinikum Regensburg, Regensburg, Germany
[8] St Johannes Hosp Duisburg, Duisburg, Germany
[9] Univ Klinikum Heidelberg, Heidelberg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.6066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6066
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer
    Kim, E. S.
    Kies, M. S.
    Glisson, B. S.
    Tsao, A.
    Ginsberg, L. E.
    Holsinger, F. C.
    Burke, B. J.
    Truong, M.
    Papadimitrakopoulou, A.
    Lippman, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial
    Yoshino, Takayuki
    Hasegawa, Yasuhisa
    Takahashi, Shunji
    Monden, Nobuya
    Homma, Akihiro
    Okami, Kenji
    Onozawa, Yusuke
    Fujii, Masato
    Taguchi, Takahide
    de Blas, Barbara
    Beier, Frank
    Tahara, Makoto
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (05) : 524 - 531
  • [33] Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
    Bauman, Julie E.
    Julian, Ricklie
    Saba, Nabil F.
    Wise-Draper, Trisha M.
    Adkins, Douglas R.
    O'Brien, Paul
    Fidler, Mary Jo
    Gibson, Michael K.
    Duvvuri, Umamaheswar
    Heath-Chiozzi, Margo
    Alvarado, Diego
    Gedrich, Richard
    Golden, Philip
    Cohen, Roger B.
    CANCERS, 2022, 14 (10)
  • [34] Weekly chemotherapy with cisplatin and docetaxel for recurrent metastatic head and neck cancer: a phase II study
    Guntinas-Lichius, O.
    Appenrodt, S.
    Veelken, F.
    Krug, B.
    EJC SUPPLEMENTS, 2005, 3 (02): : 297 - 297
  • [35] Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
    Gulati, Shuchi
    Crist, McKenzie
    Riaz, Muhammed Kashif
    Takiar, Vinita
    Lehn, Maria
    Monroe, Ilaina
    Palackdharry, Sarah
    Kurtzweil, Nicky
    Jandarov, Roman
    Harun, Nusrat
    Wise-Draper, Trisha M.
    CLINICAL CANCER RESEARCH, 2023, 29 (10) : 1906 - 1915
  • [36] An analysis of toxicity in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) receiving cetuximab, fluorouracil and cisplatin alone or with docetaxel in a phase II clinical trial (CeFCiD)
    Knoedler, M.
    Dietz, A.
    Gauler, T.
    Stoehlmacher, J.
    Gruenwald, V
    Rethwisch, V
    Frickhofen, N.
    Haxel, B.
    Schroeder, M.
    Knipping, S.
    Maschmeyer, G.
    Guntinas-Lichius, O.
    Keilholz, U.
    ONKOLOGIE, 2012, 35 : 153 - 153
  • [37] A Phase II Trial Evaluating Weekly Docetaxel and Capecitabine in Patients with Metastatic or Advanced, Locally Recurrent Head and Neck Cancers
    Zhang, Jingsong
    Lee, Julia
    Urba, Susan
    Foster, Jared
    Worden, Francis
    CANCER INVESTIGATION, 2010, 28 (09) : 910 - 916
  • [38] Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck (RMHNC).
    Ikpeazu, CV
    Murphy, BA
    Kish, B
    Cmelak, A
    Shyr, Y
    Netterville, J
    Burkey, B
    Chung, C
    Yarbrough, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 508S - 508S
  • [39] PACLITAXEL/CARBOPLATINUM plus CETUXIMAB AS SECOND LINE CHEMOTHERAPY FOR PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER
    Buentzel, J.
    Stritzel, R.
    de Vries, A.
    Muecke, R.
    Garayev, A.
    Bruns, F.
    Micke, O.
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3224 - 3224
  • [40] A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
    Koyama, Taiji
    Kiyota, Naomi
    Imamura, Yoshinori
    Boku, Shogen
    Shibata, Nobuhiro
    Satake, Hironaga
    Tanaka, Kaoru
    Hayashi, Hidetoshi
    Iwae, Shigemichi
    Onoe, Takuma
    Asada, Yukinori
    Yamazaki, Tomoko
    Nose, Taku
    Ohata, Shinya
    Kimbara, Shiro
    Nagatani, Yoshiaki
    Minami, Hironobu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345